Razan Mohty, MD (@razanmohty) Bsky

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study Bone Marrow Transplantation - Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

Happy to share our recent manuscript on outcomes of anti-CD19 #CART for #lymphoma in octogenarians (80 years of age or older).

👉🏻CR rate 71.4%
👉🏻1-year OS 61.2%
👉🏻1-year PFS 47.6%
👉🏻1-year NRM 11.6%

🙏🏻 to all collaborators

Link 🔗 rdcu.be/ebQ47

1 year ago 3 1 0 0

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) result...

Our new @BMTCTN 1703 analysis busts a few myths:
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...

1 year ago 17 5 0 0

Two incredibly important abstracts presented by @moffittnews.bsky.social myeloma investigators at #ASH24. 1/3

1 year ago 1 1 1 0

Dr. Jabbour from @mdanderson.bsky.social presents on long-term outcomes following obecabtagene autoleucel (obe-cel, Aucatzyl) stratified by depth of response by clonoSEQ NGS (sensitivity 10^-6). 84% of responders achieved clonoSEQ negativity. 1/x #ash24 #allsm

1 year ago 6 2 1 0

#ASH24 #ASH24rm

1 year ago 3 0 0 0